Erschienen in:
17.10.2019 | Editorial
Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer
verfasst von:
Gary J. R. Cook
Erschienen in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Ausgabe 1/2020
Einloggen, um Zugang zu erhalten
Excerpt
With a propensity for prostate cancer to spread to the skeleton and the recognised shortcomings of conventional imaging, such as computed tomography (CT) and bone scintigraphy (BS) in detecting skeletal metastases, there is a need for more sensitive detection of bone metastases, both at diagnosis and at biochemical recurrence (BCR). The need for more sensitive imaging is now of greater importance with the introduction of several novel therapeutics for metastatic prostate cancer that can improve morbidity and prolong survival, as well as the introduction of potentially curative treatment strategies for those with oligometastatic disease. …